Loading…

Efficacy of the modified staged method of surgical treatment for proliferative diabetic retinopathy

Background. Anti-vascular endothelial growth factor (VEGF) agents have been successfully used to reduce the incidence of perioperative and postoperative complications in patients with proliferative diabetic retinopathy (PDR). Purpose: To evaluate the efficacy of a modified staged method of surgical...

Full description

Saved in:
Bibliographic Details
Published in:Oftalmologicheskiĭ zhurnal. 2022-03, Vol.96 (1), p.30-36
Main Authors: Ponomarchuk, Vira S, Korol, A. R., Umanets, M. M.
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 36
container_issue 1
container_start_page 30
container_title Oftalmologicheskiĭ zhurnal.
container_volume 96
creator Ponomarchuk, Vira S
Korol, A. R.
Umanets, M. M.
description Background. Anti-vascular endothelial growth factor (VEGF) agents have been successfully used to reduce the incidence of perioperative and postoperative complications in patients with proliferative diabetic retinopathy (PDR). Purpose: To evaluate the efficacy of a modified staged method of surgical treatment for PDR which involves intravitreal aflibercept (IVA) injection 1-mg prior to vitrectomy. Material and Methods: This study involved 75 patients (75 eyes) with PDR. Group 1 (the control group) received vitrectomy only; Group 2, IVA 1.0 mg prior to vitrectomy; and Group 3, IVA 2.0 mg prior to vitrectomy. Results: Mean visual acuity at 2 months and 6 months was significantly better in eyes treated with aflibercept than in those not treated with aflibercept (p1-2 = 0.0001; p1-3 = 0.0001). In the early postoperative period, transient vitreous hemorrhage was observed significantly more frequently in the control group than in group 2 (p1-2 = 0.0003) or group 3 (p1-3 = 0.0004). The incidence of transient vitreous hemorrhage within 2 months after vitrectomy was also significantly higher in the control group than in group 2 (p1-2=0.09) or group 3 (p1-2=0.017). By 6 months after surgery, rubeosis developed in 5 eyes (16.1%) of the control group, and in no eye of the 44 eyes that received intravitreal aflibercept (р= 0.02). Conclusion: Our modified staged method of surgical treatment for PDR enabled an improvement in visual acuity at 2 months and 6 months after surgery; a reduction in the incidence of transient vitreous hemorrhage in the early postoperative period; and reduction in the risk of the development of iris rubeosis in the late period after surgery.
doi_str_mv 10.31288/oftalmolzh20223036
format article
fullrecord <record><control><sourceid>doaj_cross</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_eecf1ea8c5904917b6efb45edd70530e</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_eecf1ea8c5904917b6efb45edd70530e</doaj_id><sourcerecordid>oai_doaj_org_article_eecf1ea8c5904917b6efb45edd70530e</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2256-afb56f21ad3eedd8bf2a68ed20668603ad555bdb97f16466b324df1ab8a2ea2f3</originalsourceid><addsrcrecordid>eNplkN1KAzEQhYMoWGqfwJu8wGp-Ntn0Ukr9gYI3er1MNjNtZLcp2SjUp3et4o03c2Bm-M7hMHYtxY2WyrnbRAX6IfWfOyWU0kLbMzZTtVSVa2pxzmZCaFEJ25hLthjH6IWQjbO6djPWrYliB92RJ-Jlh3xIIVLEwMcC20kGLLsUvq_je95Orz0vGaEMuC-cUuaHnPpImKHED-QhgscSO56nuU8HKLvjFbsg6Edc_Oqcvd6vX1aP1eb54Wl1t6k6pYytgLyxpCQEjRiC86TAOgxKWOus0BCMMT74ZUPS1tZ6repAErwDhaBIz9nTDzckeGsPOQ6Qj22C2J4WKW9byFO2HlvEjiSC68xS1EvZeIvkazPZNsJogRNL_7C6nMYxI_3xpGhPtbf_a9dfLTN7-Q</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Efficacy of the modified staged method of surgical treatment for proliferative diabetic retinopathy</title><source>DOAJ Directory of Open Access Journals</source><creator>Ponomarchuk, Vira S ; Korol, A. R. ; Umanets, M. M.</creator><creatorcontrib>Ponomarchuk, Vira S ; Korol, A. R. ; Umanets, M. M. ; SI ; The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine ; SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"</creatorcontrib><description>Background. Anti-vascular endothelial growth factor (VEGF) agents have been successfully used to reduce the incidence of perioperative and postoperative complications in patients with proliferative diabetic retinopathy (PDR). Purpose: To evaluate the efficacy of a modified staged method of surgical treatment for PDR which involves intravitreal aflibercept (IVA) injection 1-mg prior to vitrectomy. Material and Methods: This study involved 75 patients (75 eyes) with PDR. Group 1 (the control group) received vitrectomy only; Group 2, IVA 1.0 mg prior to vitrectomy; and Group 3, IVA 2.0 mg prior to vitrectomy. Results: Mean visual acuity at 2 months and 6 months was significantly better in eyes treated with aflibercept than in those not treated with aflibercept (p1-2 = 0.0001; p1-3 = 0.0001). In the early postoperative period, transient vitreous hemorrhage was observed significantly more frequently in the control group than in group 2 (p1-2 = 0.0003) or group 3 (p1-3 = 0.0004). The incidence of transient vitreous hemorrhage within 2 months after vitrectomy was also significantly higher in the control group than in group 2 (p1-2=0.09) or group 3 (p1-2=0.017). By 6 months after surgery, rubeosis developed in 5 eyes (16.1%) of the control group, and in no eye of the 44 eyes that received intravitreal aflibercept (р= 0.02). Conclusion: Our modified staged method of surgical treatment for PDR enabled an improvement in visual acuity at 2 months and 6 months after surgery; a reduction in the incidence of transient vitreous hemorrhage in the early postoperative period; and reduction in the risk of the development of iris rubeosis in the late period after surgery.</description><identifier>ISSN: 0030-0675</identifier><identifier>EISSN: 2412-8740</identifier><identifier>DOI: 10.31288/oftalmolzh20223036</identifier><language>eng</language><publisher>Ukrainian Society of Ophthalmologists</publisher><subject>intravitreal aflibercept ; proliferative diabetic retinopathy ; vitrectomy</subject><ispartof>Oftalmologicheskiĭ zhurnal., 2022-03, Vol.96 (1), p.30-36</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,2102,27924,27925</link.rule.ids></links><search><creatorcontrib>Ponomarchuk, Vira S</creatorcontrib><creatorcontrib>Korol, A. R.</creatorcontrib><creatorcontrib>Umanets, M. M.</creatorcontrib><creatorcontrib>SI</creatorcontrib><creatorcontrib>The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine</creatorcontrib><creatorcontrib>SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"</creatorcontrib><title>Efficacy of the modified staged method of surgical treatment for proliferative diabetic retinopathy</title><title>Oftalmologicheskiĭ zhurnal.</title><description>Background. Anti-vascular endothelial growth factor (VEGF) agents have been successfully used to reduce the incidence of perioperative and postoperative complications in patients with proliferative diabetic retinopathy (PDR). Purpose: To evaluate the efficacy of a modified staged method of surgical treatment for PDR which involves intravitreal aflibercept (IVA) injection 1-mg prior to vitrectomy. Material and Methods: This study involved 75 patients (75 eyes) with PDR. Group 1 (the control group) received vitrectomy only; Group 2, IVA 1.0 mg prior to vitrectomy; and Group 3, IVA 2.0 mg prior to vitrectomy. Results: Mean visual acuity at 2 months and 6 months was significantly better in eyes treated with aflibercept than in those not treated with aflibercept (p1-2 = 0.0001; p1-3 = 0.0001). In the early postoperative period, transient vitreous hemorrhage was observed significantly more frequently in the control group than in group 2 (p1-2 = 0.0003) or group 3 (p1-3 = 0.0004). The incidence of transient vitreous hemorrhage within 2 months after vitrectomy was also significantly higher in the control group than in group 2 (p1-2=0.09) or group 3 (p1-2=0.017). By 6 months after surgery, rubeosis developed in 5 eyes (16.1%) of the control group, and in no eye of the 44 eyes that received intravitreal aflibercept (р= 0.02). Conclusion: Our modified staged method of surgical treatment for PDR enabled an improvement in visual acuity at 2 months and 6 months after surgery; a reduction in the incidence of transient vitreous hemorrhage in the early postoperative period; and reduction in the risk of the development of iris rubeosis in the late period after surgery.</description><subject>intravitreal aflibercept</subject><subject>proliferative diabetic retinopathy</subject><subject>vitrectomy</subject><issn>0030-0675</issn><issn>2412-8740</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNplkN1KAzEQhYMoWGqfwJu8wGp-Ntn0Ukr9gYI3er1MNjNtZLcp2SjUp3et4o03c2Bm-M7hMHYtxY2WyrnbRAX6IfWfOyWU0kLbMzZTtVSVa2pxzmZCaFEJ25hLthjH6IWQjbO6djPWrYliB92RJ-Jlh3xIIVLEwMcC20kGLLsUvq_je95Orz0vGaEMuC-cUuaHnPpImKHED-QhgscSO56nuU8HKLvjFbsg6Edc_Oqcvd6vX1aP1eb54Wl1t6k6pYytgLyxpCQEjRiC86TAOgxKWOus0BCMMT74ZUPS1tZ6repAErwDhaBIz9nTDzckeGsPOQ6Qj22C2J4WKW9byFO2HlvEjiSC68xS1EvZeIvkazPZNsJogRNL_7C6nMYxI_3xpGhPtbf_a9dfLTN7-Q</recordid><startdate>20220301</startdate><enddate>20220301</enddate><creator>Ponomarchuk, Vira S</creator><creator>Korol, A. R.</creator><creator>Umanets, M. M.</creator><general>Ukrainian Society of Ophthalmologists</general><scope>AAYXX</scope><scope>CITATION</scope><scope>DOA</scope></search><sort><creationdate>20220301</creationdate><title>Efficacy of the modified staged method of surgical treatment for proliferative diabetic retinopathy</title><author>Ponomarchuk, Vira S ; Korol, A. R. ; Umanets, M. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2256-afb56f21ad3eedd8bf2a68ed20668603ad555bdb97f16466b324df1ab8a2ea2f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>intravitreal aflibercept</topic><topic>proliferative diabetic retinopathy</topic><topic>vitrectomy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ponomarchuk, Vira S</creatorcontrib><creatorcontrib>Korol, A. R.</creatorcontrib><creatorcontrib>Umanets, M. M.</creatorcontrib><creatorcontrib>SI</creatorcontrib><creatorcontrib>The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine</creatorcontrib><creatorcontrib>SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"</creatorcontrib><collection>CrossRef</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Oftalmologicheskiĭ zhurnal.</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ponomarchuk, Vira S</au><au>Korol, A. R.</au><au>Umanets, M. M.</au><aucorp>SI</aucorp><aucorp>The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine</aucorp><aucorp>SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of the modified staged method of surgical treatment for proliferative diabetic retinopathy</atitle><jtitle>Oftalmologicheskiĭ zhurnal.</jtitle><date>2022-03-01</date><risdate>2022</risdate><volume>96</volume><issue>1</issue><spage>30</spage><epage>36</epage><pages>30-36</pages><issn>0030-0675</issn><eissn>2412-8740</eissn><abstract>Background. Anti-vascular endothelial growth factor (VEGF) agents have been successfully used to reduce the incidence of perioperative and postoperative complications in patients with proliferative diabetic retinopathy (PDR). Purpose: To evaluate the efficacy of a modified staged method of surgical treatment for PDR which involves intravitreal aflibercept (IVA) injection 1-mg prior to vitrectomy. Material and Methods: This study involved 75 patients (75 eyes) with PDR. Group 1 (the control group) received vitrectomy only; Group 2, IVA 1.0 mg prior to vitrectomy; and Group 3, IVA 2.0 mg prior to vitrectomy. Results: Mean visual acuity at 2 months and 6 months was significantly better in eyes treated with aflibercept than in those not treated with aflibercept (p1-2 = 0.0001; p1-3 = 0.0001). In the early postoperative period, transient vitreous hemorrhage was observed significantly more frequently in the control group than in group 2 (p1-2 = 0.0003) or group 3 (p1-3 = 0.0004). The incidence of transient vitreous hemorrhage within 2 months after vitrectomy was also significantly higher in the control group than in group 2 (p1-2=0.09) or group 3 (p1-2=0.017). By 6 months after surgery, rubeosis developed in 5 eyes (16.1%) of the control group, and in no eye of the 44 eyes that received intravitreal aflibercept (р= 0.02). Conclusion: Our modified staged method of surgical treatment for PDR enabled an improvement in visual acuity at 2 months and 6 months after surgery; a reduction in the incidence of transient vitreous hemorrhage in the early postoperative period; and reduction in the risk of the development of iris rubeosis in the late period after surgery.</abstract><pub>Ukrainian Society of Ophthalmologists</pub><doi>10.31288/oftalmolzh20223036</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0030-0675
ispartof Oftalmologicheskiĭ zhurnal., 2022-03, Vol.96 (1), p.30-36
issn 0030-0675
2412-8740
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_eecf1ea8c5904917b6efb45edd70530e
source DOAJ Directory of Open Access Journals
subjects intravitreal aflibercept
proliferative diabetic retinopathy
vitrectomy
title Efficacy of the modified staged method of surgical treatment for proliferative diabetic retinopathy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T21%3A58%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-doaj_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20the%20modified%20staged%20method%20of%20surgical%20treatment%20for%20proliferative%20diabetic%20retinopathy&rft.jtitle=Oftalmologicheski%C4%AD%20zhurnal.&rft.au=Ponomarchuk,%20Vira%20S&rft.aucorp=SI&rft.date=2022-03-01&rft.volume=96&rft.issue=1&rft.spage=30&rft.epage=36&rft.pages=30-36&rft.issn=0030-0675&rft.eissn=2412-8740&rft_id=info:doi/10.31288/oftalmolzh20223036&rft_dat=%3Cdoaj_cross%3Eoai_doaj_org_article_eecf1ea8c5904917b6efb45edd70530e%3C/doaj_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2256-afb56f21ad3eedd8bf2a68ed20668603ad555bdb97f16466b324df1ab8a2ea2f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true